Literature DB >> 15447669

Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine.

Tatyana D Sotnikova1, Evgeny A Budygin, Sara R Jones, Linda A Dykstra, Marc G Caron, Raul R Gainetdinov.   

Abstract

Beta-phenylethylamine (beta-PEA) is an endogenous amine that is found in trace amounts in the brain. It is believed that the locomotor-stimulating action of beta-PEA, much like amphetamine, depends on its ability to increase extracellular dopamine (DA) concentrations owing to reversal of the direction of dopamine transporter (DAT)-mediated DA transport. beta-PEA can also bind directly to the recently identified G protein-coupled receptors, but the physiological significance of this interaction is unclear. To assess the mechanism by which beta-PEA mediates its effects, we compared the neurochemical and behavioral effects of this amine in wild type (WT), heterozygous and 'null' DAT mutant mice. In microdialysis studies, beta-PEA, administered either systemically or locally via intrastriatal infusion, produced a pronounced outflow of striatal DA in WT mice whereas no increase was detected in mice lacking the DAT (DAT-KO mice). Similarly, in fast-scan voltammetry studies beta-PEA did not alter DA release and clearance rate in striatal slices from DAT-KO mice. In behavioral studies beta-PEA produced a robust but transient increase in locomotor activity in WT and heterozygous mice. In DAT-KO mice, whose locomotor activity and stereotypy are increased in a novel environment, beta-PEA (10-100 mg/kg) exerted a potent inhibitory action. At high doses, beta-PEA induced stereotypies in WT and heterozygous mice; some manifestations of stereotypy were also observed in the DAT-KO mice. These data demonstrate that the DAT is required for the striatal DA-releasing and hyperlocomotor actions of beta-PEA. The inhibitory action on hyperactivity and certain stereotypies induced by beta-PEA in DAT-KO mice indicate that targets other than the DAT are responsible for these effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15447669     DOI: 10.1111/j.1471-4159.2004.02721.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  26 in total

1.  Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1).

Authors:  Gregory M Miller
Journal:  J Med Chem       Date:  2012-01-20       Impact factor: 7.446

2.  Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor.

Authors:  Stefano Espinoza; Ali Salahpour; Bernard Masri; Tatyana D Sotnikova; Mirko Messa; Larry S Barak; Marc G Caron; Raul R Gainetdinov
Journal:  Mol Pharmacol       Date:  2011-06-13       Impact factor: 4.436

3.  Amphetamine potentiates the effects of β-phenylethylamine through activation of an amine-gated chloride channel.

Authors:  Bryan D Safratowich; Murad Hossain; Laura Bianchi; Lucia Carvelli
Journal:  J Neurosci       Date:  2014-03-26       Impact factor: 6.167

Review 4.  Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence.

Authors:  Marco Bortolato; Jean C Shih
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

5.  Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion-induced apoptosis through PI3K/Akt/GSK3β pathway in rats.

Authors:  Lin Chen; Xinbing Wei; Yunfeng Hou; Xiaoqian Liu; Senpeng Li; Baozhu Sun; Xinyong Liu; Huiqing Liu
Journal:  Neurochem Int       Date:  2014-01-22       Impact factor: 3.921

6.  Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice.

Authors:  Marco Bortolato; Sean C Godar; Shieva Davarian; Kevin Chen; Jean C Shih
Journal:  Neuropsychopharmacology       Date:  2009-08-26       Impact factor: 7.853

Review 7.  Trace amine-associated receptors as emerging therapeutic targets.

Authors:  Tatyana D Sotnikova; Marc G Caron; Raul R Gainetdinov
Journal:  Mol Pharmacol       Date:  2009-04-23       Impact factor: 4.436

Review 8.  Trace amine-associated receptor 1-Family archetype or iconoclast?

Authors:  David K Grandy
Journal:  Pharmacol Ther       Date:  2007-07-17       Impact factor: 12.310

9.  Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor.

Authors:  Larry S Barak; Ali Salahpour; Xiaodong Zhang; Bernard Masri; Tatyana D Sotnikova; Amy J Ramsey; Jonathan D Violin; Robert J Lefkowitz; Marc G Caron; Raul R Gainetdinov
Journal:  Mol Pharmacol       Date:  2008-06-04       Impact factor: 4.436

10.  "TAARgeting Addiction"--The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference.

Authors:  David K Grandy; Gregory M Miller; Jun-Xu Li
Journal:  Drug Alcohol Depend       Date:  2015-11-22       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.